Canadian Federal Court of Appeal Rules on Patent Register Timing in Bayer vs Amgen Case
核心洞察
The Federal Court of Appeal (搜索) upheld a decision that generic drug manufacturers are not required to address patents submitted to Health Canada's Patent Register before their filing but listed after their submission date.
The court ruled that patents are only effective on the Register once Health Canada confirms eligibility, not on the date of initial submission to the regulatory authority.
The decision creates a "freeze" mechanism protecting generic applicants from patent additions made after their submission filing date, though this outcome disadvantaged Bayer in the specific case.
On August 8, 2025, the Federal Court of Appeal (搜索) (FCA) delivered a significant ruling in pharmaceutical patent law, determining that the Minister of Health's decision to list Canadian Patent No. 2,970,315 on the Patent Register eight days after submission was reasonable. The decision in Bayer Inc (搜索) v Amgen Canada Inc (搜索), 2025 FCA 142, upholds the Federal Court's original ruling and establishes important precedent for generic drug approval processes.
Court Upholds Minister's Patent Listing Decision
The Federal Court of Appeal (搜索) rejected Bayer's challenge to the Minister of Health's interpretation of patent registration requirements. The Minister had determined that a patent must await an eligibility determination before being listed on the Register, and that generic manufacturers are not obligated to address patents that have been submitted to the Register but not yet officially listed.
The FCA found the Minister's position reasonable, emphasizing that patents are only effective on the Register once Health Canada confirms eligibility, not on the date of initial submission. This ruling clarifies the timing mechanisms that govern patent protection in Canada's pharmaceutical regulatory framework.
Regulatory "Freeze" Mechanism Protects Generic Applicants
A key aspect of the court's decision centers on section 5(4) of the Patented Medicines (Notice of Compliance) Regulations, which "freezes" the Patent Register as of the generic or biosimilar submission filing date. This mechanism shields submission applicants from later patent additions, a principle that the FCA noted is reflected in the Regulatory Impact Analysis Statement.
The court highlighted the disparity in timing between the parties: Amgen's submission filing date was the day its New Drug Submission (NDS) was submitted, while Bayer's patent listing date was the day it was found eligible, not when it was initially submitted to Health Canada.
Bayer's Arguments Rejected Despite Acknowledged Disadvantage
Bayer had argued that the Minister's interpretation was unreasonable, incorrect, and created an unfair "race" between brand-name and generic manufacturers. The company requested that the Court treat both parties consistently in terms of timing requirements.
However, the FCA rejected these arguments while acknowledging that this outcome disadvantaged Bayer. The court maintained that the Minister's decision was reasonable within the existing regulatory framework, despite the timing disadvantage it created for the patent holder.
Limited Appeal Options Remain
Following this decision, Bayer would require leave from the Supreme Court of Canada (搜索) should it wish to pursue further appeals. The ruling represents a significant development in Canadian pharmaceutical patent law, particularly regarding the timing of patent registrations and their impact on generic drug approvals.